{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T10:33:08Z","timestamp":1756463588719,"version":"3.37.3"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T00:00:00Z","timestamp":1568246400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T00:00:00Z","timestamp":1568246400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s00277-019-03798-5","type":"journal-article","created":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T19:02:31Z","timestamp":1568314951000},"page":"2561-2567","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of cerebrospinal clonal gene rearrangement in newly diagnosed non-Hodgkin\u2019s lymphoma patients"],"prefix":"10.1007","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7341-2167","authenticated-orcid":false,"given":"Boaz","family":"Nachmias","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Sandler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Slyusarevsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galina","family":"Pogrebijski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlana","family":"Kritchevsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina","family":"Ben-Yehuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neta","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moshe E.","family":"Gatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,12]]},"reference":[{"key":"3798_CR1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1177\/2040620713519729","volume":"5","author":"A Gazzola","year":"2014","unstructured":"Gazzola A, Mannu C, Rossi M, Laginestra MA, Sapienza MR, Fuligni F, Etebari M, Melle F, Sabattini E, Agostinelli C, Bacci F, Sagramoso Sacchetti CA, Pileri SA, Piccaluga PP (2014) The evolution of clonality testing in the diagnosis and monitoring of hematological malignancies. Ther Adv Hematol 5:35\u201347. \nhttps:\/\/doi.org\/10.1177\/2040620713519729","journal-title":"Ther Adv Hematol"},{"key":"3798_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/10428194.2016.1201569","volume":"58","author":"N Goldschmidt","year":"2017","unstructured":"Goldschmidt N, Darawshy F, Kleinstern G, Slyusarevsky E, Pogrebijski G, Krichevsky S, Ben-Yehuda D, Gatt ME (2017) The prognostic value of bone marrow involvement at the molecular level in aggressive lymphoma. Leuk Lymphoma 58:45\u201352. \nhttps:\/\/doi.org\/10.1080\/10428194.2016.1201569","journal-title":"Leuk Lymphoma"},{"key":"3798_CR3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jns.2006.03.012","volume":"247","author":"D Ekstein","year":"2006","unstructured":"Ekstein D, Ben-Yehuda D, Slyusarevsky E, Lossos A, Linetsky E, Siegal T (2006) CSF analysis of IgH gene rearrangement in CNS lymphoma: relationship to the disease course. J Neurol Sci 247:39\u201346. \nhttps:\/\/doi.org\/10.1016\/j.jns.2006.03.012","journal-title":"J Neurol Sci"},{"key":"3798_CR4","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.leukres.2008.09.033","volume":"33","author":"D Sayed","year":"2009","unstructured":"Sayed D, Badrawy H, Ali AM, Shaker S (2009) Immunophenotyping and immunoglobulin heavy chain gene rearrangement analysis in cerebrospinal fluid of pediatric patients with acute lymphoblastic leukemia. Leuk Res 33:655\u2013661. \nhttps:\/\/doi.org\/10.1016\/j.leukres.2008.09.033","journal-title":"Leuk Res"},{"key":"3798_CR5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S1525-1578(10)60018-9","volume":"7","author":"SR Pine","year":"2005","unstructured":"Pine SR, Yin C, Matloub YH, Sabaawy HE, Sandoval C, Levendoglu-Tugal O, Ozkaynak MF, Jayabose S (2005) Detection of central nervous system leukemia in children with acute lymphoblastic leukemia by real-time polymerase chain reaction. J Mol Diagn 7:127\u2013132. \nhttps:\/\/doi.org\/10.1016\/S1525-1578(10)60018-9","journal-title":"J Mol Diagn"},{"key":"3798_CR6","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","volume":"34","author":"N Schmitz","year":"2016","unstructured":"Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, Glass B, Scott DW, Gascoyne RD, Connors JM, Ziepert M, Pfreundschuh M, Loeffler M, Savage KJ (2016) CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 34:3150\u20133156. \nhttps:\/\/doi.org\/10.1200\/JCO.2015.65.6520","journal-title":"J Clin Oncol"},{"key":"3798_CR7","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","year":"1993","unstructured":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med 329:987\u2013994. \nhttps:\/\/doi.org\/10.1056\/NEJM199309303291402","journal-title":"N Engl J Med"},{"key":"3798_CR8","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA, Alliance, Australasian Leukaemia and Lymphoma Group, Eastern Cooperative Oncology Group, European Mantle Cell Lymphoma Consortium, Italian Lymphoma Foundation, European Organisation for Research, Treatment of Cancer\/Dutch Hemato-Oncology Group, Grupo Espa\u00f1ol de M\u00e9dula \u00d3sea, German High-Grade Lymphoma Study Group, German Hodgkin's Study Group, Japanese Lymphorra Study Group, Lymphoma Study Association, NCIC Clinical Trials Group, Nordic Lymphoma Study Group, Southwest Oncology Group, United Kingdom National Cancer Research Institute (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059\u20133067. \nhttps:\/\/doi.org\/10.1200\/JCO.2013.54.8800","journal-title":"J Clin Oncol"},{"key":"3798_CR9","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/sj.leu.2401245","volume":"13","author":"MJ Pongers-Willemse","year":"1999","unstructured":"Pongers-Willemse MJ, Seriu T, Stolz F, d'Aniello E, Gameiro P, Pisa P, Gonzalez M, Bartram CR, Panzer-Gr\u00fcmayer ER, Biondi A, San Miguel JF, van Dongen J (1999) Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets: report of the BIOMED-1 CONCERTED ACTION: investigation of minimal residual disease in acute leukemia. Leukemia 13:110\u2013118","journal-title":"Leukemia"},{"key":"3798_CR10","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/bjc.2014.405","volume":"111","author":"CY Cheah","year":"2014","unstructured":"Cheah CY, Herbert KE, O\u2019Rourke K et al (2014) A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma. Br J Cancer 111:1072\u20131079. \nhttps:\/\/doi.org\/10.1038\/bjc.2014.405","journal-title":"Br J Cancer"},{"key":"3798_CR11","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1182\/blood-2004-05-1982","volume":"105","author":"U Hegde","year":"2005","unstructured":"Hegde U (2005) High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 105:496\u2013502. \nhttps:\/\/doi.org\/10.1182\/blood-2004-05-1982","journal-title":"Blood"},{"key":"3798_CR12","doi-asserted-by":"publisher","first-page":"3222","DOI":"10.1182\/blood-2012-04-423095","volume":"120","author":"G Benevolo","year":"2012","unstructured":"Benevolo G, Stacchini A, Spina M, Ferreri AJM, Arras M, Bellio L, Botto B, Bulian P, Cantonetti M, Depaoli L, di Renzo N, di Rocco A, Evangelista A, Franceschetti S, Godio L, Mannelli F, Pavone V, Pioltelli P, Vitolo U, Pogliani EM, on behalf of the Fondazione Italiana Linfomi (2012) Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination. Blood 120:3222\u20133228. \nhttps:\/\/doi.org\/10.1182\/blood-2012-04-423095","journal-title":"Blood"},{"key":"3798_CR13","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/ijlh.12255","volume":"37","author":"L Liu","year":"2015","unstructured":"Liu L, Cao F, Wang S, Zhou J, Yang G, Wang C (2015) Detection of malignant B lymphocytes by PCR clonality assay using direct lysis of cerebrospinal fluid and low volume specimens. Int J Lab Hematol 37:165\u2013173. \nhttps:\/\/doi.org\/10.1111\/ijlh.12255","journal-title":"Int J Lab Hematol"},{"key":"3798_CR14","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1002\/cncr.25278","volume":"116","author":"JS Abramson","year":"2010","unstructured":"Abramson JS, Hellmann M, Barnes JA, Hammerman P, Toomey C, Takvorian T, Muzikansky A, Hochberg EP (2010) Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer 116:4283\u20134290. \nhttps:\/\/doi.org\/10.1002\/cncr.25278","journal-title":"Cancer"},{"key":"3798_CR15","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/bjh.13194","volume":"168","author":"AJM Ferreri","year":"2015","unstructured":"Ferreri AJM, Bruno-Ventre M, Donadoni G, Ponzoni M, Citterio G, Foppoli M, Vignati A, Scarf\u00f2 L, Sassone M, Govi S, Caligaris-Cappio F (2015) Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era. Br J Haematol 168:654\u2013662. \nhttps:\/\/doi.org\/10.1111\/bjh.13194","journal-title":"Br J Haematol"},{"key":"3798_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1365-2141.2012.09247.x","volume":"159","author":"HR Guirguis","year":"2012","unstructured":"Guirguis HR, Cheung MC, Mahrous M, Piliotis E, Berinstein N, Imrie KR, Zhang L, Buckstein R (2012) Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature. Br J Haematol 159:39\u201349. \nhttps:\/\/doi.org\/10.1111\/j.1365-2141.2012.09247.x","journal-title":"Br J Haematol"},{"key":"3798_CR17","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.blre.2011.12.001","volume":"26","author":"T Siegal","year":"2012","unstructured":"Siegal T, Goldschmidt N (2012) CNS prophylaxis in diffuse large B-cell lymphoma: if, when, how and for whom? Blood Rev 26:97\u2013106. \nhttps:\/\/doi.org\/10.1016\/j.blre.2011.12.001","journal-title":"Blood Rev"},{"issue":"52","key":"3798_CR18","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11864-018-0569-2","volume":"19","author":"R Kansara","year":"2018","unstructured":"Kansara R (2018) Central nervous system prophylaxis strategies in diffuse large B cell lymphoma. Curr Treat Options in Oncol 19(52):52. \nhttps:\/\/doi.org\/10.1007\/s11864-018-0569-2","journal-title":"Curr Treat Options in Oncol"},{"key":"3798_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2018.1564823","volume":"60","author":"N Goldschmidt","year":"2019","unstructured":"Goldschmidt N, Horowitz NA, Hefetz V et al (2019) Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse. Leuk Lymphoma 60:1\u20139. \nhttps:\/\/doi.org\/10.1080\/10428194.2018.1564823","journal-title":"Leuk Lymphoma"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03798-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-019-03798-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03798-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T23:13:12Z","timestamp":1599779592000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-019-03798-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,12]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["3798"],"URL":"https:\/\/doi.org\/10.1007\/s00277-019-03798-5","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"type":"print","value":"0939-5555"},{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2019,9,12]]},"assertion":[{"value":"28 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The retrospective data collection was approved by the local ethics committee in accordance with the Helsinki declaration standards and provided informed consent to participate in the study. All patients gave their informed consent prior to their inclusion in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}